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Abstract Lovastatin treatment caused down-regulation of the
insulin-responsive glucose transporter 4 (Glut4) and up-regula-
tion of Glut1 in 3T3-L1 adipocytes. These changes in protein
expression were associated with a marked inhibition of insulin-
stimulated glucose transport. Lovastatin had no effect on cell
cholesterol levels, but its effects were reversed by mevalonate,
demonstrating that inhibition of isoprenoid biosynthesis causes
insulin resistance in 3T3-L1 adipocytes. These findings support
the notion that whole body insulin resistance may arise as a result
of perturbations in general biochemical pathways, rather than
primary defects in insulin signalling. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
Insulin stimulates the fusion of intracellular vesicles con-
taining the glucose transporter 4 (Glut4) with the plasma
membrane, resulting in an enhanced expression of Glut4 at
the cell surface and an increased rate of glucose uptake [1,2].
Defects in the signalling and tra⁄cking pathways that regu-
late Glut4 distribution and decreased Glut4 expression levels
have all been implicated as contributing factors to insulin re-
sistance and type 2 diabetes [3^6]. Whether defects in these
insulin-regulated pathways are the primary cause of insulin
resistance or are secondary to more general cellular abnormal-
ities is unknown. It is therefore essential to identify metabolic
changes that can cause an insulin resistant state.
A number of conditions have been identi¢ed that lead to
decreased Glut4 expression and subsequent insulin resistance.
These include chronic exposure to insulin [7,8], which de-
creases Glut4 mRNA levels and protein stability, and pro-
longed exposure to tumor necrosis factor K or arachidonic
acid, which inhibit Glut4 transcription [9,10]. These decreases
in Glut4 levels are often paralleled/followed by increases in
Glut1 transcription. Recent work has shown that culturing of
3T3-L1 adipocytes in cholesterol-depleted media in the pres-
ence of an inhibitor of 3-hydroxy-3-methylglutaryl CoA
(HMG-CoA) reductase (to block cholesterol biosynthesis) sig-
ni¢cantly reduced cholesterol levels (three-fold), and resulted
in down-regulation of Glut4 and up-regulation of Glut1 [11].
The changes in Glut4/Glut1 levels were evident at both
mRNA and protein levels. Although cholesterol was clearly
reduced in these cells, the synthesis of other isoprenoids (in-
termediates in the cholesterol biosynthetic pathway) would
also be inhibited. Thus, it is not clear what impact inhibition
of isoprenoid synthesis has on the expression of Glut4 and
Glut1.
I have examined the e¡ect of inhibiting isoprenoid synthesis
(whilst maintaining normal cholesterol levels) on the expres-
sion of Glut4 and Glut1.
2. Materials and methods
2.1. Materials
Lovastatin was obtained from Calbiochem. Mevalonolactone, In-
¢nity cholesterol reagent and cytochalasin B were from Sigma (Poole,
UK). Glut1 antiserum was provided by Dr Steven Baldwin (Univer-
sity of Leeds, UK). Monoclonal insulin-responsive aminopeptidase
(IRAP) antibody was from Drs Luis Garza and Morris Birnbaum
(University of Pennsylvania, PA, USA).
2.2. Cell culture
3T3-L1 cells were grown in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) containing 10% foetal calf serum (FCS) at 37‡C in a hu-
midi¢ed atmosphere of 10% CO2. Four days following con£uence, the
cells were incubated in DMEM with 10% FCS, 1 Wg/ml insulin, 110
Wg/ml isobutylmethylxanthinine, and 0.25 WM dexamethasone for
3 days, and then in FCS-containing media with 1 Wg/ml insulin for
a further 2 days. The cells were then incubated for 3^5 days in FCS
media with or without lovastatin at the indicated concentrations.
2.3. Preparation of 3T3-L1 membranes
Cells were washed three times in HES (20 mM HEPES, 255 mM
sucrose, 1 mM EDTA, pH 7.4) and homogenised by 20 strokes of a
Dounce homogeniser in HES supplemented with a protease inhibitor
cocktail (Boehringer Mannheim). Membranes were recovered by cen-
trifugation at 196 000Ug for 1 h and resuspended in HES/protease
inhibitors.
2.4. 2-Deoxyglucose transport
Adipocytes on 6-well plates were incubated in serum-free media for
2 h. The cells were then washed three times and incubated for 30 min
at 37‡C with or without 1 WM insulin. [3H]2-Deoxyglucose (50 WM,
0.25 WCi) was added to each well for 3 min and the cells were quickly
washed in ice-cold PBS, solubilised in Triton X-100 and [3H]2-deoxy-
glucose uptake assayed by scintillation counting. Glut-speci¢c glucose
uptake was measured by subtracting values for [3H]2-deoxyglucose
uptake in the presence of 10 WM cytochalasin B.
2.5. Whole cell immuno£uorescence
Adipocytes grown on collagen-coated coverslips were washed in
PBS and ¢xed in methanol at 320‡C for 6 min. The ¢xed cells
0014-5793 / 01 / $20.00 ß 2001 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 3 0 0 7 - 1
*Fax: (44)-141-3304620.
E-mail address: l.chamberlain@bio.gla.ac.uk (L.H. Chamberlain).
Abbreviations: HMG-CoA, 3-hydroxy-3-methylglutaryl CoA; Glut,
glucose transporter; IRAP, insulin-responsive aminopeptidase
FEBS 25400 26-10-01
FEBS 25400 FEBS Letters 507 (2001) 357^361
were washed in PBS and incubated for 10 min in PBS/1% foetal
bovine serum (FBS). Antibodies against Glut4 and Glut1 (both at
1:100) in PBS/1% FBS were added to the cells for 1 h, and washed
three times in PBS/5% goat serum. The cells were then incubated with
secondary FITC-conjugated antibodies (1:200) in PBS/5% goat serum
for 1 h, washed three times in PBS and processed for immuno£uores-
cence analysis.
3. Results
To discriminate between e¡ects of cholesterol and other
isoprenoids on Glut4 and Glut1 expression, 3T3-L1 adipo-
cytes were cultured in cholesterol-containing media with or
without lovastatin. Lovastatin inhibits mevalonate formation
by inhibiting the activity of HMG-CoA reductase, which cat-
alyses the committed step in cholesterol biosynthesis. Treat-
ment with 5 WM lovastatin for 3 days did not signi¢cantly
a¡ect membrane cholesterol levels as assayed using a choles-
terol esterase/cholesterol oxidase colourimetric assay (ratio of
cholesterol to protein was 0.070 þ 0.0036 for control cells and
0.071 þ 0.0048 for lovastatin-treated cells, n = 6). This implies
that the major source of cholesterol is from uptake, rather
than de novo synthesis. In contrast, incubation of 3T3-L1
adipocytes with 10 mM methyl-L-cyclodextrin for 30 min re-
sulted in a 40% reduction in cellular cholesterol levels (not
shown), con¢rming that the assay system can reliably detect
cholesterol depletion. As an alternative measure of cholesterol
levels, thin layer chromatography (TLC) analysis was per-
formed on lyophilised cell pellets that had been subjected to
an extended period of treatment with an increased concentra-
tion of lovastatin (10 WM for 7 days). TLC analysis revealed
that even this prolonged treatment with lovastatin did not
decrease cellular cholesterol levels (cholesterol levels in lova-
statin-treated cells were 112 þ 5% that of control cells, n = 3).
The lack of e¡ect of lovastatin on cholesterol levels is con-
sistent with the work of Le Lay et al. [11] who showed that
the e¡ects of cholesterol depletion on SREBP-2 target genes
was reversed when 1 Wg/ml cholesterol was included in the
growth media. This reversal occurred despite a sustained in-
hibition of cholesterol biosynthesis (by mevastatin), implying
that cholesterol uptake and not de novo synthesis controls
cellular cholesterol levels. Using this protocol, it is therefore
possible to examine what impact inhibition of isoprenoid syn-
thesis has on Glut4 and Glut1 expression.
Lovastatin treatment had a marked e¡ect on both Glut4
and Glut1 expression levels (Fig. 1A,B), down-regulating
Glut4 and up-regulating Glut1. These e¡ects were maximal
at 5 WM over 3 days of treatment. Glut4 levels were reduced
to 43.2 þ 6.6% of control cells (n = 6, P6 0.001), whereas
Glut1 expression was increased by 240 þ 31% (n = 6,
P6 0.01). The e¡ect of lovastatin on Glut4 and Glut1 expres-
sion was prevented when 250 WM mevalonate was also in-
cluded in the growth media (Fig. 1A), strongly suggesting
that the observed e¡ects were due to an inhibition of HMG-
CoA reductase and isoprenoid biosynthesis. In addition, ex-
pression of the Glut4 vesicle protein IRAP was reduced to
75.5 þ 6.6% (n = 6, P6 0.01) of control levels in lovastatin-
treated cells.
Le Lay et al. [11] found that cholesterol depletion led to a
2.6-fold increase in caveolin 2 mRNA levels. In contrast, I
found that lovastatin treatment produced a small but statisti-
cally signi¢cant decrease in caveolin 2 protein levels
(79 þ 5.5% of control levels, n = 6, P6 0.01). This suggests
that some of the changes in gene expression observed by Le
Lay and colleagues were attributable to cholesterol depletion
(caveolin 2), whereas others (Glut4 and Glut1) were caused by
inhibiting the synthesis of cholesterol precursors.
To assess the time dependence of lovastatin e¡ects on
Glut4, Glut1 and IRAP expression, samples of adipocytes
were analysed at various times following addition of lovasta-
tin. 5 WM lovastatin was added to 3T3-L1 adipocytes on the
¢fth day following the initiation of di¡erentiation, and protein
levels analysed at subsequent 24 h intervals. Fig. 2A,B shows
that lovastatin-induced increases in Glut1 expression were evi-
dent after 1 day of treatment, whereas Glut4 expression was
signi¢cantly decreased after 2 days. In comparison, decreased
expression of IRAP was evident after 3 days lovastatin treat-
ment. The longer time (compared to Glut1) required to ob-
serve changes in Glut4 and IRAP expression are consistent
with the idea that lovastatins e¡ects are occurring at the
Fig. 1. Concentration dependence of lovastatin e¡ects on protein ex-
pression. 3T3-L1 adipocytes at d5 post-di¡erentiation were cultured
in various concentrations of lovastatin (as indicated) for 72 h. 250
WM mevalonate was also added to the samples indicated. Cells were
homogenised and membranes recovered by centrifugation. Equal
amounts of the membranes were separated by SDS^PAGE and
transferred to nitrocellulose for immunoblotting analysis using anti-
bodies speci¢c for Glut4 and Glut1. A: A representative immuno-
blot, whereas (B) is averaged data quanti¢ed from three separate ex-
periments, expressed as means þ standard error.
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mRNA level [11]. Note that lovastatin treatment resulted in
the generation of a lower molecular weight Glut1 species
(Figs. 1A and 2A), which may arise as a result of ine⁄cient
glycosylation (as discussed later).
To further analyse the e¡ect of lovastatin treatment on
cellular Glut4/Glut1 expression, adipocytes were examined
by whole cell immuno£uorescence. By this method, Glut4
levels also appeared to be diminished in lovastatin-treated
cells (Fig. 3B) compared to control cells (Fig. 3A). Note
that the laser power setting was three times greater for the
image shown of lovastatin-treated, Glut4-stained cells than
for control cells. In contrast, lovastatin-treated cells stained
for Glut1 (Fig. 3D) appeared brighter than the corresponding
control cells (Fig. 3C). Although the images shown do not
provide quantitative evidence of changes in proteins expres-
sion, they do provide evidence that the changes in Glut4 and
Glut1 expression are occurring throughout the cell popula-
tion, rather than in a sub-population of cells. Fig. 3 also
shows that lovastatin-treated 3T3-L1 adipocytes display a typ-
ical adipocyte morphology, with several fat droplets per cell.
Fig. 2. Time dependence of lovastatin e¡ects on protein expression.
Lovastatin (5 WM) was added to 3T3-L1 adipocytes at day 5 post-
di¡erentiation, and membranes were prepared from the cells at sub-
sequent 24 h intervals to day 10. Equal amounts of membrane pro-
teins were separated by SDS^PAGE and transferred to nitrocellu-
lose for immunoblotting analysis using antibodies against Glut4,
Glut1 and IRAP. A: A representative immunoblot, whereas (B) is
averaged data quanti¢ed from three separate experiments, expressed
as means þ standard error.
Fig. 3. Immuno£uorescence analysis of Glut4 and Glut1 expression
in lovastatin-treated 3T3-L1 adipocytes. Cells were incubated with
or without 5 WM lovastatin for 3 days and processed for immuno-
£uorescence analysis as detailed in Section 2. Shown are representa-
tive images of Glut4 in control (A) and lovastatin-treated cells (B),
and Glut1 in control (C) and lovastatin-treated cells (D).
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To assess whether the decreased expression of Glut4 is as-
sociated with insulin resistance, insulin-stimulated 2-deoxyglu-
cose transport into control and lovastatin-treated cells was
assayed. Fig. 4 shows that 2-deoxyglucose transport in re-
sponse to insulin challenge was signi¢cantly reduced in cells
treated with lovastatin, demonstrating that defects in isopre-
noid metabolism can lead to cellular insulin resistance.
4. Discussion
Numerous studies have examined the consequences on in-
sulin action and whole body glucose homeostasis of mutating
components of the insulin signalling cascade and glucose
transport machinery [12^15]. Not surprisingly, in the majority
of these cases insulin action is impaired. In contrast, the ef-
fects of perturbing general cellular pathways on insulin action
has not been examined in any great detail. This study dem-
onstrates that adipocytes become insulin resistant when iso-
prenoid biosynthesis is inhibited. In light of this, it is sug-
gested that insulin resistance at the whole body level may
arise as a result of imbalance in general biochemical path-
ways, and e¡ects observed on insulin signalling pathways
may occur secondary to this.
Previous work had shown that cholesterol depletion is as-
sociated with changes in Glut4 and Glut1 protein expression
[11]. However, the protocol used in that study (combined
cholesterol starvation and inhibited cholesterol biosynthesis)
allowed the possibility that changes in gene expression were
attributable to a decreased synthesis of isoprenoid cholesterol
precursors, rather than to cholesterol itself. The procedure
used in the current study lead to an inhibition of isoprenoid
biosynthesis whilst maintaining normal cellular cholesterol
levels (through an exogenous cholesterol source). Indeed, the
lack of e¡ect of lovastatin on cholesterol levels in 3T3-L1
adipocytes is consistent with a previous study [16]. Although
cholesterol levels were normal, the synthesis of other isopre-
noids were likely inhibited as mevalonate reversed the e¡ects
of lovastatin.
Possible mechanisms whereby lovastatin inhibits protein ex-
pression include an inhibition of protein prenylation (farnesol
and geranylgeraniol are both intermediates in the cholesterol
biosynthesis pathway). In this regard it is interesting to note
that over-expression of the small GTPase ras in adipose tissue
leads to an increased expression of Glut1 [17]. However, as
lovastatin treatment would be predicted to inhibit ras activa-
tion, it is unlikely that the e¡ects on Glut1 expression are
linked to ras function. In addition, over-expression of ras
was shown to have no e¡ect on Glut4 expression [17].
Other points of note from this study are that the increased
expression of Glut1 is unlikely to represent a compensatory
mechanism to counter the decreased Glut4 expression. This is
because increased expression of Glut1 is evident after 1 day of
lovastatin treatment, whereas decreased Glut4 expression is
observed following 2 days of treatment. Thus, it is likely
that there is a coordinated (but opposite) regulatory mecha-
nism controlling Glut4 and Glut1 expression. Interestingly,
the observed decrease in IRAP expression followed the de-
crease in Glut4 expression. Although it is possible that this
relates to di¡erent half-lives of the proteins, it may be that a
decreased expression of Glut4 leads to a decrease in IRAP
levels, as the two proteins appear to extensively colocalise
and to tra⁄c identically in adipocytes [18^21]. Finally, lova-
statin treatment resulted in the synthesis of a lower molecular
weight Glut1 species, which probably represents a non-glyco-
sylated or partially glycosylated form of Glut1. This may arise
because of lovastatin-mediated inhibition of dolichol biosyn-
thesis (an important molecule for protein glycosylation) [22],
alternatively, the increased expression of Glut1 may lead to
ine⁄cient glycosylation.
The results described in this paper are particularly relevant
in light of very recent work showing that decreased expression
of Glut4 in adipose tissue of transgenic mice causes insulin
resistance in adipocytes, muscle and liver [15]. Thus, adipo-
cyte-speci¢c down-regulation of Glut4 may lead to pro-
nounced whole body insulin resistance and ultimately type 2
diabetes.
Acknowledgements: I am very grateful to Dr Fran Platt and Gabriele
Reinkensmeier (University of Oxford, UK) for TLC analysis of cho-
lesterol levels, and to Professor Gwyn Gould (University of Glasgow,
UK) for critical reading of the prepared manuscript. Glut1 antibody
was provided by Dr Steve Baldwin (University of Leeds, UK) and
IRAP antibody was donated by Drs Luis Garza and Morris Birn-
baum (University of Pennsylvania, PA, USA). This work was sup-
ported by the Diabetes Research and Wellness Foundation.
References
[1] Elmendorf, J.S. and Pessin, J.E. (1999) Exp. Cell Res. 253, 55^
62.
[2] Holman, G.D. and Sandoval, I.V. (2001) Trends Cell Biol. 11,
173^179.
[3] Pessin, J.E. and Saltiel, A.R. (2000) J. Clin. Invest. 106, 165^169.
[4] Saltiel, A.R. (2001) Cell 104, 517^529.
[5] Garvey, W.T., Maianu, L., Huecksteadt, T.P., Birnbaum, M.J.,
Molina, M.J. and Ciaraldi, T.P. (1991) J. Clin. Invest. 87, 1072^
1081.
[6] Carvalho, E., Jansson, P.-A., Nagaev, I., Wenthzel, A.-M. and
Smith, U. (2001) FASEB J. 15, 1101^1103.
[7] Kozka, I.J., Clark, A.E. and Holman, G.D. (1991) J. Biol. Chem.
266, 11726^11731.
[8] Maier, V.H., Melvin, D.R., Lister, C.A., Chapman, H., Gould,
G.W. and Murphy, G.J. (2000) Diabetes 49, 618^625.
Fig. 4. E¡ect of lovastatin on insulin-stimulated glucose uptake into
3T3-L1 adipocytes. Cells were grown in the presence or absence of
5 WM lovastatin for 3 days. The cells were then incubated in serum-
free media for 2 h, and [3H]2-deoxyglucose uptake measured follow-
ing treatment with (+) or without (3) 1 WM insulin for 20 min. The
data are expressed as pmol glucose uptake/min/well (n = 3).
FEBS 25400 26-10-01
L.H. Chamberlain/FEBS Letters 507 (2001) 357^361360
[9] Stephens, J.M., Lee, J. and Pilch, P.F. (1997) J. Biol. Chem. 272,
971^976.
[10] Tebbey, P.W., McGowan, K.M., Stephens, J.M., Buttke, T.M.
and Pekala, P.H. (1994) J. Biol. Chem. 269, 639^644.
[11] Le Lay, S., Krief, S., Farnier, C., Lefrere, I., Le Liepvre, X.,
Bazin, R., Ferre, P. and Dugail, I. (2001) J. Biol. Chem. 276,
16904^16910.
[12] Tamemoto, H., Kadowaki, T., Tobe, K., Yagi, T., Sakura, H.,
Hayakawa, T., Terauchi, Y., Ueki, K., Kaburagi, Y., Satoh, S.,
Sekihara, H., Yoshioka, S., Horikoshi, H., Furuta, Y., Ikawa,
Y., Kasuga, M., Yazaki, Y. and Aizawa, S. (1994) Nature 372,
182^186.
[13] Withers, D.J., Sanchez-Gutierrez, J.C., Towery, H., Ren, J.M.,
Burks, D.J., Ren, J.-M., Previs, S., Zhang, Y., Bernal, D., Pons,
S., Shulman, G.I., Bonner-Weir, S. and White, M.F. (1998) Na-
ture 391, 900^904.
[14] Michael, M.D., Kulkarni, R.N., Postic, C., Previs, S.F., Shul-
man, G.I., Magnuson, M.A. and Kahn, C.R. (2000) Mol. Cell
6, 87^97.
[15] Abel, E.D., Peroni, O., Kim, J.K., Kim, Y.-B., Boss, O., Hadro,
E., Minnemann, T., Shulman, G.I. and Kahn, B.B. (2001) Nature
409, 729^733.
[16] Nishio, E., Tomiyama, K., Nakata, H. and Watanabe, Y. (1996)
Eur. J. Pharmacol. 301, 203^206.
[17] Houseknecht, K.L., Zhu, A.X., Gnudi, L., Hamann, A., Zierath,
J.R., Tozzo, E., Flier, J.S. and Kahn, B.B. (1996) J. Biol. Chem.
271, 11347^11355.
[18] Kandror, K.V., Yu, L. and Pilch, P.F. (1994) J. Biol. Chem. 269,
30777^30780.
[19] Kandror, K.V., Coderre, L., Pushkin, A.V. and Pilch, P.F. (1995)
Biochem. J. 307, 383^390.
[20] Martin, S., Rice, J.E., Gould, G.W., Keller, S.R., Slot, J.W. and
James, D.E. (1997) J. Cell Sci. 110, 2281^2291.
[21] Garza, L.A. and Birnbaum, M.J. (2000) J. Biol. Chem. 275,
2560^2567.
[22] Ciosek Jr., C.P., Magnin, D.R., Harrity, T.W., Logan, J.V.H.,
Dickson Jr., J.K., Gordon, E.M., Hamilton, K.A., Jolibois,
K.G., Kunselman, L.K., Lawrence, R.M., Mookhtiar, K.A.,
Rich, L.C., Slusarchyk, D.A., Sulsky, R.B. and Biller, S.A.
(1993) J. Biol. Chem. 268, 24832^24837.
FEBS 25400 26-10-01
L.H. Chamberlain/FEBS Letters 507 (2001) 357^361 361
